Pyxis Oncology (NASDAQ:PYXS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Pyxis Oncology (NASDAQ:PYXS) from a sell rating to a hold rating in a research report report published on Saturday.

PYXS has been the subject of several other reports. Royal Bank Of Canada reduced their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Stephens increased their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a report on Monday, November 24th. HC Wainwright boosted their price objective on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.20.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.37 on Friday. The firm has a market capitalization of $85.30 million, a price-to-earnings ratio of -0.86 and a beta of 1.45. The company has a 50 day moving average price of $1.49 and a 200 day moving average price of $2.49. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55.

Institutional Trading of Pyxis Oncology

Hedge funds have recently modified their holdings of the stock. Maia Wealth LLC acquired a new stake in Pyxis Oncology during the 4th quarter worth $25,000. Engineers Gate Manager LP bought a new stake in shares of Pyxis Oncology during the fourth quarter worth $26,000. Fox Run Management L.L.C. bought a new position in Pyxis Oncology during the 4th quarter worth about $26,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Pyxis Oncology during the second quarter worth about $26,000. Finally, Avanza Fonder AB bought a new position in shares of Pyxis Oncology during the 4th quarter worth approximately $31,000. 39.09% of the stock is owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.